CRISPR Therapeutics Reports Q1 Revenue of $1.4M
Reports Q1 revenue $1.4M, consensus $4.25M. "The first quarter reflected continued execution across CRISPR Therapeutics' platform," said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics. "We expanded zugo-cel into new autoimmune indications and advanced multiple in vivo liver-directed programs toward the clinic, while CASGEVY continued its momentum. With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics."
